Business Context and Reporting Period
This Form 8-K was filed by ENDRA Life Sciences Inc. on July 15, 2024. The report addresses a critical regulatory event regarding the company's listing status on The Nasdaq Capital Market. The company is incorporated in Delaware and its common stock trades under the symbol NDRA.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status; it does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data point disclosed is the trading price of the common stock, which closed below $0.10 per share for 10 consecutive trading days ending July 12, 2024.
Material Changes
- Delisting Determination: On July 15, 2024, Nasdaq notified the company that it failed to meet the Minimum Bid Price Requirement (Rule 5550(a)(2)) and determined to delist the common stock from The Nasdaq Capital Market.
- Price Threshold Breach: The delisting action was triggered because the bid price closed below $0.10 per share for 10 consecutive trading days, a stricter threshold than the initial $1.00 non-compliance notice received in May 2024.
- Appeal Filed: On July 16, 2024, the company requested a hearing before a Nasdaq Hearings Panel to appeal the delisting determination. This request automatically stays the delisting action pending the hearing outcome.
Guidance, Outlook, and Risks
Management Commentary and Strategy: The company is monitoring its stock price and plans to seek stockholder approval at its Annual Meeting on August 6, 2024, for a reverse stock split. The proposed ratio is between 1-for-20 and 1-for-50, with the final ratio to be determined by the Board of Directors.
Risks and Contingencies:
- Uncertainty of Compliance: There is no assurance that the Nasdaq Hearings Panel will grant a compliance period or that the company will ultimately regain compliance with listing requirements.
- Forward-Looking Statements: The filing includes standard disclaimers that statements regarding the hearing outcome and the reverse stock split are forward-looking and subject to risks and uncertainties.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearings Panel appeal scheduled after July 16, 2024.
- Confirm the specific reverse stock split ratio approved by stockholders at the August 6, 2024 Annual Meeting.
- Monitor the definitive proxy statement (filed June 25, 2024) for details on the voting proposals.
- Track the daily closing bid price of NDRA to assess if it remains below the $0.10 threshold pending the hearing.